99 related articles for article (PubMed ID: 23759730)
21. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
Dunne RF; Hezel AF
Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
[TBL] [Abstract][Full Text] [Related]
22. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Pathol Int; 2013 Mar; 63(3):176-82. PubMed ID: 23530562
[TBL] [Abstract][Full Text] [Related]
23. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic cancer development and progression: remodeling the model.
Real FX; Cibrián-Uhalte E; Martinelli P
Gastroenterology; 2008 Sep; 135(3):724-8. PubMed ID: 18692502
[No Abstract] [Full Text] [Related]
25. KRAS Mutations With No GNAS Mutations in an Intraductal Papillary Mucinous Neoplasm: Are There Common Pathways With Pancreatic Ductal Adenocarcinoma? Lessons From an Extended IPMN, Covering the Entire Pancreas.
Tampakis A; Tampaki EC; Posabella A; Zettl A; Kouraklis G; von Flüe M; Guenin MO
Pancreas; 2017 Jan; 46(1):e5-e7. PubMed ID: 27977634
[No Abstract] [Full Text] [Related]
26. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
27. NR5A2 discovering compounds that block tumor growth in PDAC.
Fletterick R
J Surg Oncol; 2017 Jul; 116(1):89-93. PubMed ID: 28445593
[TBL] [Abstract][Full Text] [Related]
28. Atypical flat lesions derive from pancreatic acinar cells.
von Figura G; Fahrenkrog-Petersen L; Hidalgo-Sastre A; Hartmann D; Hüser N; Schmid RM; Hebrok M; Roy N; Esposito I
Pancreatology; 2017; 17(3):350-353. PubMed ID: 28473229
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration.
Hosoda W; Takagi T; Mizuno N; Shimizu Y; Sano T; Yamao K; Yatabe Y
Pathol Int; 2010 May; 60(5):358-64. PubMed ID: 20518885
[TBL] [Abstract][Full Text] [Related]
30. Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer.
Marchese R; Muleti A; Brozzetti S; Gandini O; Brunetti E; French D
Br J Cancer; 2004 Jun; 90(11):2243. PubMed ID: 15150585
[No Abstract] [Full Text] [Related]
31. Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions.
Lubeseder-Martellato C; Alexandrow K; Hidalgo-Sastre A; Heid I; Boos SL; Briel T; Schmid RM; Siveke JT
EBioMedicine; 2017 Feb; 15():90-99. PubMed ID: 28057438
[TBL] [Abstract][Full Text] [Related]
32. [Mutant K-ras gene in pathogenesis of pancreatic ductal adenocarcinoma].
Guan J; Chen J
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):62-5. PubMed ID: 22455858
[No Abstract] [Full Text] [Related]
33. Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer.
Wauters E; Sanchez-Arévalo Lobo VJ; Pinho AV; Mawson A; Herranz D; Wu J; Cowley MJ; Colvin EK; Njicop EN; Sutherland RL; Liu T; Serrano M; Bouwens L; Real FX; Biankin AV; Rooman I
Cancer Res; 2013 Apr; 73(7):2357-67. PubMed ID: 23370328
[TBL] [Abstract][Full Text] [Related]
34. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.
Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX
Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178
[TBL] [Abstract][Full Text] [Related]
35. Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in transgenic rodents.
Grippo PJ; Sandgren EP
Int J Cancer; 2012 Sep; 131(5):1243-8. PubMed ID: 22024988
[TBL] [Abstract][Full Text] [Related]
36. Acinar Cell-Enriched-MicroRNA-802 Connects the Dots Between Kras Signaling, Acinar Ductal Metaplasia, and Pancreatic Cancer.
Schmittgen TD; Sempere LF
Gastroenterology; 2022 Jan; 162(1):48-50. PubMed ID: 34662582
[No Abstract] [Full Text] [Related]
37. Somatostatin receptor subtype 2 as pancreatic tumorigenesis suppressor: identification of a new targetable signaling node.
Crawford HC
Gastroenterology; 2015 Jun; 148(7):1279-81. PubMed ID: 25921374
[No Abstract] [Full Text] [Related]
38. Detection of K-ras point mutation at codon 12 in pancreatic diseases: a study in a Brazilian casuistic.
Kubrusly MS; Cunha JE; Bacchella T; Abdo EE; Jukemura J; Penteado S; Morioka CY; de Souza LJ; Machado MC
JOP; 2002 Sep; 3(5):144-51. PubMed ID: 12221329
[TBL] [Abstract][Full Text] [Related]
39. What we have learned about pancreatic cancer from mouse models.
Pérez-Mancera PA; Guerra C; Barbacid M; Tuveson DA
Gastroenterology; 2012 May; 142(5):1079-92. PubMed ID: 22406637
[No Abstract] [Full Text] [Related]
40. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
